OncoMatch

OncoMatch/Clinical Trials/NCT06622941

Study to ONO-4538 in Patients With Rhabdoid Tumor

Is NCT06622941 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies ONO-4538 for rhabdoid tumor.

Phase 2RecruitingOno Pharmaceutical Co. LtdNCT06622941Data as of May 2026

Treatment: ONO-4538Investigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Prior therapy

Min 1 prior line

Must have received: chemotherapy — for rhabdoid Tumors

Patients who are refractory or intolerant to one or more regimens of chemotherapy for rhabdoid Tumors

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify